Description: MedX Health Corp. is a medical device company. The Company is focused on research, development, manufacturing and distribution of phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode (LED). Its products are offered to the rehabilitation market for treating pain, tissue damage, swelling and inflammation. It offers SIAscopy, which is a medical device that is used to scan suspicious moles and lesions. Its SIMSYS-MoleMate Skin Imaging System is a non-invasive skin screening procedure for moles and lesions. Its SIMSYS uses SIAscopy providing detail and information from approximately two millimeters beneath the skin. Its MoleMate is a non-invasive, rapid and painless screening device that has been designed with and for general practitioners and skin specialists. Its SIAMETRICS allows cosmetic formulators and active ingredient manufacturers to measure and quantify the concentrations of melanin, hemoglobin and collagen in living human skin.
Home Page: medxhealth.com
MDX Technical Analysis
1495 Bonhill Road
Mississauga,
ON
L5T 1M2
Canada
Phone:
905-670-4428
Officers
| Name | Title |
|---|---|
| Mr. Louie Canitano | COO & MD of Light Therapy Products |
| Mr. Michael Druhan | Pres of Dermatological Services & Products |
| Mr. Naman Demaghlatrous BAMA | Pres, CEO & Director |
| C H Freeman | Interim Chief Financial Officer |
| Mr. Paul Karam | Sales and Marketing Director of Europe, Middle East & Africa |
| Dr. Daniel A. Kaute | Managing Director of Europe |
| Mr. Scott Naughton | Managing Director of US Operations |
| Mr. Christopher H. Freeman | Sec. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 13.4953 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 12.5997 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |